

BIOMARIN PHARMACEUTICAL INC  
 Form 4  
 May 09, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIENAIME JEAN JACQUES**

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

(Last) (First) (Middle)  
**C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.**  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**05/05/2016**

**SAN RAFAEL, CA 94901**  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)		
				(A) or (D)	Price				
				Code	V	Amount			
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	A	\$ 12.99	10,000	I	Shares held in irrevocable trust for Guillaume Bienaime <sup>(2)</sup>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	S	10,000	D	\$ 80.1489 <sup>(3)</sup>	0	I	Shares held in irrevocable

									trust for Guillaume Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	A	\$ 12.99	10,000	I	Shares held in irrevocable trust for Pierre Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	S	10,000	D	\$ 80.1489 <u>(3)</u>	0	I	Shares held in irrevocable trust for Pierre Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	A	\$ 12.99	10,000	I	Shares held in irrevocable trust for Paul Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	D	\$ 80.1489 <u>(3)</u>	0	I	Shares held in irrevocable trust for Paul Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	A	\$ 12.99	10,000	I	Shares held in irrevocable trust for Marc Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	S	10,000	D	\$ 80.1489 <u>(3)</u>	0	I	Shares held in irrevocable trust for Marc Bienaime <u>(2)</u>
	05/05/2016 <sup>(1)</sup>	05/05/2016	M	20,000	A	\$ 12.99	20,000	I	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock									Shares held in irrevocable trust for Aurelie Mitsuki Bienaime & Anais Kimiko Bienaime <u>(2)</u>
Common Stock	05/05/2016 <sup>(1)</sup>	05/05/2016	S	20,000	D	\$ 80.1489	0	I	Shares held in irrevocable trust for Aurelie Mitsuki Bienaime & Anais Kimiko Bienaime <u>(2)</u>
Common Stock	05/06/2016	05/06/2016	F	5,479	D	\$ 80.8	390,156	D	
Common Stock							25,758	I	Shares held by Bienaime Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number

										of Shares
Stock Option (right to buy) Common Stock	\$ 12.99	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	11/11/2006	05/10/2016	Common Stock	10,000	
Stock Option (right to buy) Common Stock	\$ 12.99	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	11/11/2006	05/10/2016	Common Stock	10,000	
Stock Option (right to buy) Common Stock	\$ 12.99	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	11/11/2006	05/10/2016	Common Stock	10,000	
Stock Option (right to buy) Common Stock	\$ 12.99	05/05/2016 <sup>(1)</sup>	05/05/2016	M	10,000	11/11/2006	05/10/2016	Common Stock	10,000	
Stock Option (right to buy) Common Stock	\$ 12.99	05/05/2016 <sup>(1)</sup>	05/05/2016	M	20,000	11/11/2006	05/10/2016	Common Stock	20,000	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	X		Chief Executive Officer	

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

05/09/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 trading plan executed on August 17, 2015.

(2) The reporting person's spouse is the trustee of each child's trust.

(3) The price in column 4 is a weighted average price. The price actually received ranged from \$79.46 to \$82.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(4) Reflects the numbers of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.